Berlin/Cologne/Hamburg, March 08, 2021 – PCR tests are the most reliable method for diagnosing Corona infection. Health offices and physicians are using PCR-tests. Travel abroad, German national league football games and lifting of quarantine are not possible without PCR testing. A positive rapid or self-test must be verified by PCR test. The catch: a swab […]
Alacris Theranostics startet Seedmatch-Crowdfunding-Kampagne für einzigartige computergestützte Tumoranalyse zur Optimierung von KrebstherapienJeder Mensch ist anders und Tumore besonders – ein Grund warum viele Krebstherapien heute immer noch scheitern. Damit der Krebs erfolgreich bekämpft werden kann, muss eine Therapie die Schwachstellen ihres Gegners erkennen können, also den individuellen Eigenheiten des Tumors angepasst werden. Alacris‘ Comprehensive Molecular […]
European Commission supports DigiTwins On Friday, 18th of May, DigiTwins received an invitation from the European Commission to enter the nextstage of the competition to become an EU Flagship for Future and Emerging Technologies. DigiTwins, alarge research initiative in Europe and beyond aims at revolutionizing healthcare and biomedical researchfor the benefit of citizens and society […]
New biomarkers for bowel cancer treatment Scientists can predict in the lab whether a drug will be effective for individual colorectal tumors Colorectal carcinomas arise in different forms, so all treatments do not work for all patients. OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative Joint Undertaking, has conducted one of Europe’s largest […]
The quality management of Alacris Theranostics GmbH has been certified by TÜV Süd according to ISO 9001:2015. Alacris therefore fulfills the requirements for a quality management system according to the latest revision of ISO 9001. Alacris focuses on personalized medicine and requires its own state-of-the-art next-generation sequencing lab with an efficient sequencing and data analysis […]
An international group of scientists from 6 countries bring together their expertise to develop a combined experimental and systems biology platform for predictive modelling of cancer signalling. The EU Horizon 2020 funded project, co-ordinated by Alacris Theranostics GmbH, Berlin, will run for 5 years with a budget of almost 11 million euros. The European Research […]
Alacris is proud to be one of the four finalists in the category „Start-Up-Companies“. A committee of representatives from industry and science considered the 200 applications. Criteria for the award alongside the level of innovation are marketability, innovation management and sustainability of the business concept. The oldest innovation award in the world is awarded in […]
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments Berlin, 29th July 2015 – Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. It can occur in various forms, differing not only by specific changes in the genetic material of the leukemia cells […]
The Deutsche Innovationspreis 2015 was awarded in Munich on Friday, April 24th. Alacris is the proud winner in the category Small and Medium Sized Enterprises.Our innovation ModCellTM convinced the jury. They agree with us that our systems biology approach not only helps physicians and clinics to find the right drug for the right patient. It […]
Alacris is one of the partners of CANCER-ID, a newly formed European consortium funded by the Innovative Medicines Initiative (IMI). CANCER-ID consists of currently 33 partners from 13 countries aiming at the establishment of standard protocols for and clinical validation of blood-based biomarkers. The consortium brings together experts from academic and clinical research, innovative Small-to-Medium […]